Journal
JOURNAL OF EXPERIMENTAL MEDICINE
Volume 214, Issue 7, Pages 1937-1947Publisher
ROCKEFELLER UNIV PRESS
DOI: 10.1084/jem.20160724
Keywords
-
Categories
Funding
- Perkins Fund
- National Institutes of Health [1K08AI116979-01]
- Jeffrey Modell Foundation Translational Research Program grant
Ask authors/readers for more resources
The treatment of chronic mucocutaneous ulceration is challenging, and only some patients respond selectively to inhibitors of tumor necrosis factor-alpha (TNF). TNF activates opposing pathways leading to caspase-8-mediated apoptosis as well as nuclear factor kappa B (NF-kappa B)-dependent cell survival. We investigated the etiology of autosomal-dominant, mucocutaneous ulceration in a family whose proband was dependent on anti-TNF therapy for sustained remission. A heterozygous mutation in RELA, encoding the NF-kappa B subunit RelA, segregated with the disease phenotype and resulted in RelA haploinsufficiency. The patients' fibroblasts exhibited increased apoptosis in response to TNF, impaired NF-kappa B activation, and defective expression of NF-kappa B-dependent antiapoptotic genes. Rela+/-mice have similarly impaired NF-kappa B activation, develop cutaneous ulceration from TNF exposure, and exhibit severe dextran sodium sulfate-induced colitis, ameliorated by TNF inhibition. These findings demonstrate an essential contribution of biallelic RELA expression in protecting stromal cells from TNF-mediated cell death, thus delineating the mechanisms driving the effectiveness of TNF inhibition in this disease.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available